{"id":19123,"date":"2022-03-10T10:23:16","date_gmt":"2022-03-10T18:23:16","guid":{"rendered":"https:\/\/ameripharmaspe.wpengine.com\/staging\/?p=18711"},"modified":"2026-03-19T14:38:30","modified_gmt":"2026-03-19T21:38:30","slug":"jakafi-ruxolitinib","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/","title":{"rendered":"Jakafi (ruxolitinib)"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#How_Does_Jakafi_Work\" >\u00bfC\u00f3mo funciona Jakafi?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#Benefits_of_Treatment\" >Beneficios del tratamiento<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#What_Is_Jakafi_Used_For\" >\u00bfPara qu\u00e9 se utiliza Jakafi?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#How_To_Take_Jakafi\" >C\u00f3mo tomar Jakafi<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#Dosage\" >Dosificaci\u00f3n<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#Myelofibrosis\" >Mielofibrosis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#Polycythemia_Vera\" >Policitemia vera<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#Acute_Graft-Versus-Host_Disease\" >Enfermedad aguda de injerto contra hu\u00e9sped<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#Chronic_Graft-Versus-Host_Disease\" >Enfermedad cr\u00f3nica de injerto contra hu\u00e9sped<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#Jakafi_Dose_Modifications\" >Modificaciones de dosis de Jakafi<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#Concomitant_Use_With_Strong_CYP3A4_Inhibitors\" >Uso concomitante con inhibidores potentes del CYP3A4<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#Concomitant_Use_With_Strong_CYP3A4_Inducers\" >Uso concomitante con inductores potentes del CYP3A4<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#Kidney_Dysfunction\" >Disfunci\u00f3n renal<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#Liver_Dysfunction\" >Disfunci\u00f3n hep\u00e1tica<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#Duration_of_Therapy\" >Duraci\u00f3n de la terapia<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#Drug_Interactions\" >Interacciones farmacol\u00f3gicas<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#Monitoring_and_Follow-Up\" >Seguimiento y control<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#Side_Effects\" >Efectos secundarios<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#Jakafi_for_Specific_Populations\" >Jakafi para poblaciones espec\u00edficas<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#Pregnant_Women\" >Mujeres embarazadas<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#Breastfeeding_Women\" >Mujeres que amamantan<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_Does_Jakafi_Work\"><\/span>\u00bfC\u00f3mo funciona Jakafi?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Jakafi (ruxolitinib) es un inhibidor de la prote\u00edna quinasa que inhibe ciertas enzimas llamadas <a href=\"https:\/\/www.sciencedirect.com\/topics\/neuroscience\/janus-kinase\">Janus quinasas<\/a> Las quinasas Janus (JAK) participan en la producci\u00f3n de c\u00e9lulas sangu\u00edneas y la se\u00f1alizaci\u00f3n inmunitaria. En la mielofibrosis (c\u00e1ncer de m\u00e9dula \u00f3sea) o la policitemia vera (un trastorno sangu\u00edneo poco com\u00fan), las quinasas Janus se encuentran hiperactivas, lo que provoca una producci\u00f3n descontrolada de c\u00e9lulas sangu\u00edneas que pueden acumularse en otros \u00f3rganos, como el bazo, causando su agrandamiento. El ruxolitinib inhibe v\u00edas de se\u00f1alizaci\u00f3n espec\u00edficas y, por lo tanto, detiene esta sobreproducci\u00f3n de c\u00e9lulas sangu\u00edneas.<\/span><\/p>\n\n\n\n<p>Las quinasas Janus forman parte de una v\u00eda de se\u00f1alizaci\u00f3n conocida como v\u00eda JAK-STAT, que ayuda a regular la producci\u00f3n de c\u00e9lulas sangu\u00edneas, la inflamaci\u00f3n y la funci\u00f3n inmunitaria. Cuando esta v\u00eda se hiperactiva, puede provocar una producci\u00f3n excesiva de c\u00e9lulas sangu\u00edneas e inflamaci\u00f3n, lo que contribuye a la aparici\u00f3n de s\u00edntomas de la enfermedad.<\/p>\n\n\n\n<p>Al inhibir las enzimas JAK1 y JAK2, Jakafi ayuda a reducir la se\u00f1alizaci\u00f3n an\u00f3mala, lo que puede mejorar s\u00edntomas como el agrandamiento del bazo, la fatiga, los sudores nocturnos y el picor. Dado que la se\u00f1alizaci\u00f3n JAK tambi\u00e9n interviene en la funci\u00f3n inmunitaria, el tratamiento puede afectar al recuento sangu\u00edneo y aumentar el riesgo de infecci\u00f3n, por lo que se requiere un seguimiento regular.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Benefits_of_Treatment\"><\/span><strong>Beneficios del tratamiento<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Jakafi puede proporcionar varios beneficios para pacientes con mielofibrosis, policitemia vera o enfermedad de injerto contra hu\u00e9sped, entre ellos:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Reducci\u00f3n del tama\u00f1o del bazo<\/li>\n\n\n\n<li>Mejora de los s\u00edntomas relacionados con la enfermedad, como fatiga, sudores nocturnos, dolor \u00f3seo y picaz\u00f3n.<\/li>\n\n\n\n<li>Mejor control de la enfermedad cuando otros tratamientos no son eficaces o no se toleran.<\/li>\n\n\n\n<li>Una opci\u00f3n de tratamiento que permite ahorrar esteroides para la enfermedad de injerto contra hu\u00e9sped en algunos pacientes.<\/li>\n<\/ul>\n\n\n\n<p>Los resultados individuales pueden variar y pueden ser necesarias varias semanas o meses para experimentar todos los beneficios.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Is_Jakafi_Used_For\"><\/span>\u00bfPara qu\u00e9 se utiliza Jakafi?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><b>Mielofibrosis: <\/b><span data-preserver-spaces=\"true\">Jakafi est\u00e1 indicado para el tratamiento de la mielofibrosis (MF) de riesgo intermedio o alto. Esto incluye la MF primaria, la MF post-policitemia vera y la MF post-trombocitemia esencial en adultos.<\/span><span style=\"font-weight: 400;\">&nbsp;<\/span><\/li>\n\n\n\n<li><b>Policitemia vera:<\/b> <span data-preserver-spaces=\"true\">Jakafi est\u00e1 indicado para el tratamiento de la policitemia vera (PV) en adultos que han experimentado una respuesta inadecuada o intolerancia a la hidroxiurea.<\/span><\/li>\n\n\n\n<li><b>Enfermedad de injerto contra hu\u00e9sped aguda:<\/b> <span data-preserver-spaces=\"true\">Jakafi est\u00e1 indicado para el tratamiento de la enfermedad de injerto contra hu\u00e9sped aguda refractaria a esteroides (EICHa) en pacientes adultos y pedi\u00e1tricos mayores de 12 a\u00f1os de edad.&nbsp;<\/span><\/li>\n\n\n\n<li><b>Enfermedad cr\u00f3nica de injerto contra hu\u00e9sped: <\/b><span data-preserver-spaces=\"true\">Jakafi est\u00e1 indicado para el tratamiento de la enfermedad de injerto contra hu\u00e9sped cr\u00f3nica (EICHc) en pacientes adultos y pedi\u00e1tricos (mayores de 12 a\u00f1os) despu\u00e9s del fracaso de una o dos l\u00edneas de terapia sist\u00e9mica.<\/span><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_To_Take_Jakafi\"><\/span>C\u00f3mo tomar Jakafi<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>El Jakafi se toma por v\u00eda oral, generalmente dos veces al d\u00eda, seg\u00fan lo prescrito por su m\u00e9dico.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Jakafi se puede tomar con o sin alimentos.<br><\/li>\n\n\n\n<li>Tome las dosis a la misma hora todos los d\u00edas.<br><\/li>\n\n\n\n<li>Trague los comprimidos enteros a menos que su m\u00e9dico le indique lo contrario.<br><\/li>\n\n\n\n<li>Si olvida una dosis, s\u00e1ltela y tome la siguiente dosis a la hora programada.<br><\/li>\n\n\n\n<li>No tome dos dosis al mismo tiempo para compensar una dosis olvidada.<br><\/li>\n<\/ul>\n\n\n\n<p>Siga siempre las instrucciones de su m\u00e9dico cuando tome Jakafi.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dosage\"><\/span>Dosificaci\u00f3n<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Myelofibrosis\"><\/span>Mielofibrosis<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">La dosis inicial recomendada se basa en el recuento de plaquetas:&nbsp;&nbsp;<\/span><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><span style=\"font-weight: 400;\">Para plaquetas entre 50.000\/mm\u00b3 y 100.000\/mm\u00b3: 5 mg dos veces al d\u00eda<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Para plaquetas entre 100.000\/mm\u00b3 y 200.000\/mm\u00b3: 15 mg dos veces al d\u00eda<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Para plaquetas &gt; 200.000\/mm\u00b3: 20 mg dos veces al d\u00eda<\/span><\/li>\n<\/ul>\n\n\n\n<p><span style=\"font-weight: 400;\">Se realizan an\u00e1lisis de sangre antes de iniciar la terapia, cada 2 a 4 semanas hasta que las dosis se estabilicen y luego seg\u00fan est\u00e9 cl\u00ednicamente indicado.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Su m\u00e9dico titular\u00e1 y ajustar\u00e1 las dosis en funci\u00f3n de la seguridad, la eficacia y el recuento de plaquetas actual.<\/span><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Polycythemia_Vera\"><\/span>Policitemia vera<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">Para la policitemia vera, la dosis recomendada es<\/span> <span style=\"font-weight: 400;\">10 mg dos veces al d\u00eda.<\/span><\/p>\n\n\n\n<p>Los an\u00e1lisis de sangre se controlan peri\u00f3dicamente seg\u00fan est\u00e9 cl\u00ednicamente indicado.<\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Su m\u00e9dico titular\u00e1 y ajustar\u00e1 las dosis en funci\u00f3n de la seguridad, la eficacia y el recuento continuo de hemoglobina y plaquetas.<\/span><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Acute_Graft-Versus-Host_Disease\"><\/span>Enfermedad aguda de injerto contra hu\u00e9sped<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">Para la enfermedad de injerto contra hu\u00e9sped aguda, la dosis recomendada es<\/span> <span style=\"font-weight: 400;\">5 mg administrados por v\u00eda oral dos veces al d\u00eda.<\/span><\/p>\n\n\n\n<p>Los an\u00e1lisis de sangre se controlan peri\u00f3dicamente seg\u00fan est\u00e9 cl\u00ednicamente indicado.<\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Su m\u00e9dico titular\u00e1 y ajustar\u00e1 las dosis en funci\u00f3n de la seguridad, la eficacia y el recuento absoluto de neutr\u00f3filos (RAN) y el nivel de bilirrubina en curso.<\/span><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Chronic_Graft-Versus-Host_Disease\"><\/span>Enfermedad cr\u00f3nica de injerto contra hu\u00e9sped<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">Para la enfermedad de injerto contra hu\u00e9sped cr\u00f3nica, la dosis recomendada es de 10 mg administrados por v\u00eda oral dos veces al d\u00eda.<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Los an\u00e1lisis de sangre se controlan peri\u00f3dicamente seg\u00fan est\u00e9 cl\u00ednicamente indicado.<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Su m\u00e9dico titular\u00e1 y ajustar\u00e1 las dosis en funci\u00f3n de la seguridad, la eficacia y el nivel actual de ANC y bilirrubina.<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Jakafi_Dose_Modifications\"><\/span>Modificaciones de dosis de Jakafi<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Concomitant_Use_With_Strong_CYP3A4_Inhibitors\"><\/span>Uso concomitante con inhibidores potentes del CYP3A4<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">Ciertos medicamentos que son <\/span><a href=\"https:\/\/www.uptodate.com\/contents\/image?imageKey=CARD%2F76992\"><span style=\"font-weight: 400;\">Inhibidores del CYP3A4<\/span><\/a><span style=\"font-weight: 400;\">Medicamentos como el fluconazol aumentan la concentraci\u00f3n de Jakafi en sangre. Esto puede aumentar el riesgo de reacciones adversas. Informe a su m\u00e9dico sobre todos los medicamentos que est\u00e9 tomando antes de comenzar a tomar Jakafi, ya que podr\u00eda ser necesario reducir la dosis si se toma con inhibidores del CYP3A4.&nbsp;<\/span><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Concomitant_Use_With_Strong_CYP3A4_Inducers\"><\/span>Uso concomitante con inductores potentes del CYP3A4<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">Ciertos medicamentos inductores del CYP3A4 disminuyen la concentraci\u00f3n de Jakafi en sangre. Por lo tanto, esto puede reducir su eficacia. Informe a su m\u00e9dico sobre todos los medicamentos que est\u00e9 tomando antes de comenzar a tomar Jakafi, ya que podr\u00eda ser necesario ajustar la dosis si se toma con alg\u00fan inductor del CYP3A4.&nbsp;<\/span><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Kidney_Dysfunction\"><\/span>Disfunci\u00f3n renal<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">Si tiene insuficiencia renal, ser\u00e1 necesario ajustar su dosis. Si tiene e<\/span><span style=\"font-weight: 400;\">enfermedad renal en etapa II<\/span> <span style=\"font-weight: 400;\">(<\/span><span style=\"font-weight: 400;\">En pacientes con enfermedad renal cr\u00f3nica terminal (ESRD) que no requieren di\u00e1lisis, se debe evitar el uso de Jakafi. Informe a su m\u00e9dico si padece alg\u00fan tipo de insuficiencia renal.&nbsp;<\/span><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Liver_Dysfunction\"><\/span>Disfunci\u00f3n hep\u00e1tica<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">Si tiene insuficiencia hep\u00e1tica, ser\u00e1 necesario ajustar su dosis. Informe a su m\u00e9dico si padece cualquier tipo de insuficiencia hep\u00e1tica.&nbsp;<\/span><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Duration_of_Therapy\"><\/span>Duraci\u00f3n de la terapia<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">Su m\u00e9dico podr\u00eda esperar hasta 6 meses para determinar si el Jakafi le funciona. Si no observa mejor\u00eda despu\u00e9s de 6 meses de tratamiento, es posible que le indique que suspenda el medicamento.&nbsp;&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Es importante que tome Jakafi exactamente como se lo recetaron. No deje de tomarlo sin antes consultar con su m\u00e9dico. La \u00fanica excepci\u00f3n es si experimenta sangrado abundante. En ese caso, deje de tomar Jakafi y llame a su m\u00e9dico de inmediato.<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Drug_Interactions\"><\/span>Interacciones farmacol\u00f3gicas<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>El Jakafi puede interactuar con otros medicamentos y suplementos.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Los inhibidores o inductores potentes de CYP3A4 pueden afectar los niveles de Jakafi.<\/li>\n\n\n\n<li>Otros medicamentos inmunosupresores pueden aumentar el riesgo de infecci\u00f3n.<\/li>\n\n\n\n<li>En general, se deben evitar las vacunas vivas durante el tratamiento.<\/li>\n\n\n\n<li>Los suplementos a base de hierbas, como la hierba de San Juan, pueden interferir con el tratamiento.<\/li>\n<\/ul>\n\n\n\n<p>Informe siempre a su m\u00e9dico sobre todos los medicamentos, suplementos y vacunas que est\u00e9 tomando antes de comenzar el tratamiento con Jakafi.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Monitoring_and_Follow-Up\"><\/span>Seguimiento y control<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>El seguimiento regular es una parte importante del tratamiento con Jakafi.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Se realizan an\u00e1lisis de sangre para controlar los gl\u00f3bulos rojos, los gl\u00f3bulos blancos y las plaquetas.<\/li>\n\n\n\n<li>Se puede controlar la funci\u00f3n hep\u00e1tica y renal.<\/li>\n\n\n\n<li>Los ajustes de dosis son comunes y se basan en los resultados de laboratorio y los efectos secundarios.<\/li>\n<\/ul>\n\n\n\n<p>Los programas de seguimiento pueden cambiar con el tiempo dependiendo de c\u00f3mo responda al tratamiento.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Side_Effects\"><\/span>Efectos secundarios<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Los efectos secundarios m\u00e1s comunes son:&nbsp;<\/span><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/my.clevelandclinic.org\/health\/diseases\/14430-thrombocytopenia\"><span style=\"font-weight: 400;\">Trombocitopenia<\/span><\/a><span style=\"font-weight: 400;\"> (plaquetas bajas)<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Anemia (recuento bajo de gl\u00f3bulos rojos)&nbsp;<\/span><\/li>\n\n\n\n<li><a href=\"https:\/\/my.clevelandclinic.org\/health\/diseases\/21058-neutropenia\"><span style=\"font-weight: 400;\">Neutropenia<\/span><\/a><span style=\"font-weight: 400;\"> (recuento bajo de gl\u00f3bulos blancos)<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Riesgo de infecci\u00f3n (es decir, tuberculosis, leucoencefalopat\u00eda multifocal progresiva, herpes z\u00f3ster y hepatitis B)&nbsp;<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">moretones<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Mareo<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Dolor de cabeza<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Diarrea<\/span><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Jakafi_for_Specific_Populations\"><\/span>Jakafi para poblaciones espec\u00edficas<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pregnant_Women\"><\/span>Mujeres embarazadas<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">No se debe usar Jakafi durante el embarazo ni al planificar un embarazo. Se desconoce si Jakafi puede da\u00f1ar al feto.<\/span><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Breastfeeding_Women\"><\/span>Mujeres que amamantan<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">No amamante durante el tratamiento ni durante las 2 semanas posteriores a la \u00faltima dosis. Se desconoce si el Jakafi pasa a la leche materna.&nbsp;<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Jakafi (ruxolitinib) es un inhibidor de la prote\u00edna quinasa que inhibe ciertas enzimas llamadas quinasas Janus (JAK), las cuales participan en la producci\u00f3n de c\u00e9lulas sangu\u00edneas y la se\u00f1alizaci\u00f3n inmunitaria. En la mielofibrosis (c\u00e1ncer de m\u00e9dula \u00f3sea) o la policitemia vera (un trastorno sangu\u00edneo poco com\u00fan), las quinasas Janus est\u00e1n hiperactivas, lo que provoca una producci\u00f3n descontrolada de c\u00e9lulas sangu\u00edneas que pueden acumularse en otros \u00f3rganos, como el bazo, causando su agrandamiento.<\/p>","protected":false},"author":9,"featured_media":19124,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[64],"tags":[9],"class_list":["post-19123","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-discontinued","tag-dr-stephanie-shieh"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Jakafi (Ruxolitinib) - AmeriPharma\u00ae Specialty Care<\/title>\n<meta name=\"description\" content=\"Jakafi (ruxolitinib) is a protein kinase inhibitor that inhibits certain enzymes called Janus kinases (JAK).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jakafi (Ruxolitinib) - AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"og:description\" content=\"Jakafi (ruxolitinib) is a protein kinase inhibitor that inhibits certain enzymes called Janus kinases (JAK).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-10T18:23:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-19T21:38:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"855\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Stephanie Shieh, PharmD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Stephanie Shieh, PharmD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/jakafi-ruxolitinib\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/jakafi-ruxolitinib\\\/\"},\"author\":{\"name\":\"Dr. Stephanie Shieh, PharmD\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/person\\\/fa3e6923d70031df69b97d6c635ff5c8\"},\"headline\":\"Jakafi (Ruxolitinib)\",\"datePublished\":\"2022-03-10T18:23:16+00:00\",\"dateModified\":\"2026-03-19T21:38:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/jakafi-ruxolitinib\\\/\"},\"wordCount\":1132,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/jakafi-ruxolitinib\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/jakafi.jpeg\",\"keywords\":[\"Dr. Stephanie Shieh\"],\"articleSection\":[\"Discontinued\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/jakafi-ruxolitinib\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/jakafi-ruxolitinib\\\/\",\"name\":\"Jakafi (Ruxolitinib) - AmeriPharma\u00ae Specialty Care\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/jakafi-ruxolitinib\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/jakafi-ruxolitinib\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/jakafi.jpeg\",\"datePublished\":\"2022-03-10T18:23:16+00:00\",\"dateModified\":\"2026-03-19T21:38:30+00:00\",\"description\":\"Jakafi (ruxolitinib) is a protein kinase inhibitor that inhibits certain enzymes called Janus kinases (JAK).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/jakafi-ruxolitinib\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/jakafi-ruxolitinib\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/jakafi-ruxolitinib\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/jakafi.jpeg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/jakafi.jpeg\",\"width\":1280,\"height\":855},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/jakafi-ruxolitinib\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jakafi (Ruxolitinib)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/person\\\/fa3e6923d70031df69b97d6c635ff5c8\",\"name\":\"Dr. Stephanie Shieh, PharmD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/17407fcaa2338528a97840a39d751fc8d0c3680456bf6472a12061869c935718?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/17407fcaa2338528a97840a39d751fc8d0c3680456bf6472a12061869c935718?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/17407fcaa2338528a97840a39d751fc8d0c3680456bf6472a12061869c935718?s=96&d=mm&r=g\",\"caption\":\"Dr. Stephanie Shieh, PharmD\"},\"description\":\"Dr. Stephanie Shieh, PharmD was born in Kentucky and raised in Southern Los Angeles. She attended the Western University of Health Sciences and has been a practicing pharmacist for 7 years. The most rewarding part of her job is seeing her patients happy - whether it\u2019s helping them understand their medication, catching a drug interaction, or being able to communicate with their doctor to improve their therapy. She is currently precepting students from Marshall B. Ketchum University. In her free time, she enjoys spending quality time with her husband and 2 daughters. They love playing outside, doing arts and crafts, and having family dinner.\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/stephanie-shieh\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Jakafi (Ruxolitinib) - AmeriPharma\u00ae Atenci\u00f3n especializada","description":"Jakafi (ruxolitinib) es un inhibidor de la prote\u00edna quinasa que inhibe ciertas enzimas llamadas quinasas Janus (JAK).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/","og_locale":"es_MX","og_type":"article","og_title":"Jakafi (Ruxolitinib) - AmeriPharma\u00ae Specialty Care","og_description":"Jakafi (ruxolitinib) is a protein kinase inhibitor that inhibits certain enzymes called Janus kinases (JAK).","og_url":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2022-03-10T18:23:16+00:00","article_modified_time":"2026-03-19T21:38:30+00:00","og_image":[{"width":1280,"height":855,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg","type":"image\/jpeg"}],"author":"Dr. Stephanie Shieh, PharmD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Stephanie Shieh, PharmD","Est. reading time":"6 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/"},"author":{"name":"Dr. Stephanie Shieh, PharmD","@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/person\/fa3e6923d70031df69b97d6c635ff5c8"},"headline":"Jakafi (Ruxolitinib)","datePublished":"2022-03-10T18:23:16+00:00","dateModified":"2026-03-19T21:38:30+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/"},"wordCount":1132,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg","keywords":["Dr. Stephanie Shieh"],"articleSection":["Discontinued"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/","url":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/","name":"Jakafi (Ruxolitinib) - AmeriPharma\u00ae Atenci\u00f3n especializada","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg","datePublished":"2022-03-10T18:23:16+00:00","dateModified":"2026-03-19T21:38:30+00:00","description":"Jakafi (ruxolitinib) es un inhibidor de la prote\u00edna quinasa que inhibe ciertas enzimas llamadas quinasas Janus (JAK).","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg","width":1280,"height":855},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/jakafi-ruxolitinib\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/zh\/"},{"@type":"ListItem","position":2,"name":"Jakafi (Ruxolitinib)"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/es\/#website","url":"https:\/\/ameripharmaspecialty.com\/es\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/es\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/person\/fa3e6923d70031df69b97d6c635ff5c8","name":"Dra. Stephanie Shieh, PharmD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/17407fcaa2338528a97840a39d751fc8d0c3680456bf6472a12061869c935718?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/17407fcaa2338528a97840a39d751fc8d0c3680456bf6472a12061869c935718?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/17407fcaa2338528a97840a39d751fc8d0c3680456bf6472a12061869c935718?s=96&d=mm&r=g","caption":"Dr. Stephanie Shieh, PharmD"},"description":"La Dra. Stephanie Shieh, doctora en farmacia, naci\u00f3 en Kentucky y se crio en el sur de Los \u00c1ngeles. Estudi\u00f3 en la Universidad Western de Ciencias de la Salud y lleva 7 a\u00f1os ejerciendo como farmac\u00e9utica. Lo m\u00e1s gratificante de su trabajo es ver a sus pacientes felices, ya sea ayud\u00e1ndolos a comprender sus medicamentos, detectar interacciones farmacol\u00f3gicas o comunicarse con su m\u00e9dico para mejorar su terapia. Actualmente imparte clases particulares a estudiantes de la Universidad Marshall B. Ketchum. En su tiempo libre, disfruta de pasar tiempo de calidad con su esposo y sus dos hijas. Les encanta jugar al aire libre, hacer manualidades y cenar en familia.","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/stephanie-shieh\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg",1280,855,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-150x150.jpeg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-300x200.jpeg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-768x513.jpeg",768,513,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-1024x684.jpeg",1024,684,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg",1280,855,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg",1280,855,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg",600,401,false],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-330x220.jpeg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-1146x380.jpeg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-86x57.jpeg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-167x112.jpeg",167,112,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-280x187.jpeg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-370x247.jpeg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-960x641.jpeg",960,641,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg",1280,855,false]},"uagb_author_info":{"display_name":"Dr. Stephanie Shieh, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/stephanie-shieh\/"},"uagb_comment_info":3,"uagb_excerpt":"Jakafi (ruxolitinib) is a protein kinase inhibitor that inhibits certain enzymes called Janus kinases (JAK), which are involved in blood cell production and immune signaling. In myelofibrosis (bone marrow cancer) or polycythemia vera (a rare blood disorder), the Janus kinases are overactive, which leads to uncontrolled production of blood cells that can accumulate in other&hellip;","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg",1280,855,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg",1280,855,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg",1280,855,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-150x150.jpeg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-300x200.jpeg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-1024x684.jpeg",1024,684,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg",1280,855,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg",1280,855,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg",600,401,false],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-330x220.jpeg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-1146x380.jpeg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-86x57.jpeg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-167x112.jpeg",167,112,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-280x187.jpeg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-370x247.jpeg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi-960x641.jpeg",960,641,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/03\/jakafi.jpeg",1280,855,false]},"rttpg_author":{"display_name":"Dr. Stephanie Shieh, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/stephanie-shieh\/"},"rttpg_comment":3,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/discontinued\/\" rel=\"category tag\">Discontinued<\/a>","rttpg_excerpt":"Jakafi (ruxolitinib) is a protein kinase inhibitor that inhibits certain enzymes called Janus kinases (JAK), which are involved in blood cell production and immune signaling. In myelofibrosis (bone marrow cancer) or polycythemia vera (a rare blood disorder), the Janus kinases are overactive, which leads to uncontrolled production of blood cells that can accumulate in other&hellip;","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/19123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=19123"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/19123\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/19124"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=19123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=19123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=19123"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}